Leading Researchers to Discuss Biomarkers for Mild Traumatic Brain Injury at ADLM Conference in Anaheim

Experts to Address Biomarkers at Upcoming ADLM Meeting

On July 27, 2026, two prominent members of BRAINBox Solutions' Scientific Advisory Board (SAB) will take part in a significant panel discussion at the ADLM's Annual Scientific Meeting in Anaheim, CA. This panel will focus on the innovative use of biomarkers in the diagnosis and prognosis of mild traumatic brain injury (mTBI), commonly referred to as concussion or Acute Traumatic Encephalopathy (ATE).

The panel, titled "Biomarkers of Traumatic Brain Injury: New Guidance from the National Institute for Neurological Disorders and Stroke," will be moderated by Dr. Alan Wu, a respected professor at the UCSF School of Medicine and chief of laboratories at San Francisco General Hospital. Alongside him, Dr. Frank Peacock IV, a professor at Baylor College of Medicine and a leader in emergency medicine research, will also share insights.

This discussion is particularly notable as the field transitions towards more objective measures for assessing the risk of ATE. Donna Edmonds, CEO of BRAINBox Solutions, remarked on this progress, emphasizing the importance of this session in shaping clinical practices related to brain injuries. She stated, "The integration of biomarkers and neurocognitive assessment through artificial intelligence promises a new standard in diagnostic accuracy."

During the session, Dr. Wu will cover the critical analytical requirements necessary for TBI biomarker testing, shedding light on how results are reported while considering biological variations. Meanwhile, Dr. Peacock will present his findings on defining Acute Traumatic Encephalopathy and will provide updates on the HeadSmart II trial. This pivotal trial involves testing over 2,000 samples and aims to collect data that will support regulatory submissions to the U.S. Food and Drug Administration (FDA) for BRAINBox's advanced TBI diagnostic test.

The BRAINBox test is particularly groundbreaking as it incorporates a proprietary panel of patented blood biomarkers that can deliver results in moments, whether through point-of-care instruments or standard laboratory setups. Additionally, it integrates neurocognitive testing, culminating in a unified score that evaluates the injury's severity and any accompanying post-concussive symptoms.

BRAINBox Solutions is at the forefront of developing a multi-modal, AI-enhanced approach to diagnosing and prognosing mild traumatic brain injuries. Their commitment to establishing a clinical best-practice standard is evident in the robust leadership and expertise among their team, which includes leading physicians and scientists dedicated to this critical field.

As the medical community gathers at one of the leading international laboratory medicine conferences, the insights shared in this panel are expected to catalyze significant advancements in the understanding and treatment of mild traumatic brain injuries. Edmonds believes that defining new guidelines based on sound research and expert opinions will pave the way for improved patient care and intervention strategies.

This important meeting highlights BRAINBox Solutions' role as a leader in the development of effective diagnostic and prognostic tools for TBI, potentially revolutionizing how such injuries are understood and treated.

For more information about BRAINBox Solutions and their innovative work, visit www.brainboxinc.com.